- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.08. | Dicot Pharma AB Q2 Sales Decline | 7 | RTTNews | ||
| DICOT PHARMA Aktie jetzt für 0€ handeln | |||||
| 20.08. | Dicot Pharma AB: Dicot Pharma presents interim report Q2 2026 and invites to a webcast | 238 | GlobeNewswire (Europe) | Uppsala, Sweden, August 20, 2026. Dicot Pharma AB publishes its interim report for the second quarter of 2026. The report is available as an attached document and on www.dicotpharma.com. The company... ► Artikel lesen | |
| 01.07. | Dicot Pharma AB: Dicot Pharma recruits Cecilia Driving as new Chief Financial Officer | 206 | GlobeNewswire (Europe) | Uppsala, Sweden, July 1, 2026. Dicot Pharma AB announces that Cecilia Driving has been appointed as new Chief Financial Officer (CFO). She will take up the position on September 1, succeeding Björn... ► Artikel lesen | |
| 30.06. | New equity right for trading, Dicot Pharma AB | 444 | GlobeNewswire | At the request of Dicot Pharma AB, equity rights will be traded on First North Growth Market as from 01 July 2026.
Security name:
DICOT PHARMA AB TO7
Short name:
DICOT... ► Artikel lesen | |
| 25.06. | Dicot Pharma AB: Dicot Pharma receives FDA clearance to initiate the first part of the Phase 2b study with LIB-01 in the U.S. | 941 | GlobeNewswire (Europe) | Uppsala, Sweden, June 25, 2026. Dicot Pharma AB announces that the company has received clearance from the U.S. Food and Drug Administration (FDA) to initiate the first part (Part I) of the Phase 2b... ► Artikel lesen | |
| 23.06. | New last trading day for paid subscription units (BTU) of Dicot Pharma AB | 279 | GlobeNewswire | At the request of Dicot Pharma AB, the last trading day in Dicot Pharma AB's paid subscription units will be changed from 2026-06-24 to 2026-06-25.
Instrument:
Paid subscription units
Short... ► Artikel lesen | |
| 09.06. | Dicot Pharma AB: Dicot Pharma announces final outcome in the oversubscribed rights issue and carries out directed share issues | 689 | GlobeNewswire (Europe) | Uppsala, Sweden, June 9, 2026. Dicot Pharma AB announced on June 4, 2026, the preliminary outcome of the rights issue of units of approximately SEK 210 million (the "Rights Issue"). Today, the company... ► Artikel lesen | |
| 04.06. | Dicot Pharma AB: Dicot Pharma announces preliminary outcome in oversubscribed rights issue | 450 | GlobeNewswire (Europe) | Uppsala, Sweden, June 4, 2026. Dicot Pharma AB ("Dicot Pharma" or the "Company") today announces the preliminary outcome of the rights issue of units of approximately SEK 210 million (the "Rights Issue")... ► Artikel lesen | |
| 03.06. | Decision by the Disciplinary Committee regarding Dicot Pharma AB | 261 | GlobeNewswire | Stockholm, June 3, 2026 The Disciplinary Committee of Nasdaq Stockholm has found that Dicot Pharma AB (the "Company") has not breached the rules of Nasdaq Stockholm (the "Rulebook") and has therefore... ► Artikel lesen | |
| 01.06. | Dicot Pharma AB: Dicot Pharma receives patent approval in Japan for LIB-01 | 217 | GlobeNewswire (Europe) | Uppsala, Sweden, June 1, 2026. Dicot Pharma has been granted a new patent in Japan for the active substance in LIB-01. The patent strengthens the intellectual property of the company's drug candidate... ► Artikel lesen | |
| 29.05. | Dicot Pharma AB: Dicot Pharma announces the final subscription date for units in the ongoing rights issue | 512 | GlobeNewswire (Europe) | Uppsala, Sweden, May 29, 2026. Thursday, June 4, 2026, is the final day for subscription in Dicot Pharma AB's ("Dicot Pharma" or "the Company") ongoing rights issue of units, consisting of shares and... ► Artikel lesen | |
| 27.05. | Dicot Pharma AB: Dicot Pharma receives indications of interest for approx. SEK 15.6 million from existing shareholders in the ongoing rights issue | 409 | GlobeNewswire (Europe) | Uppsala, Sweden, May 27, 2026. Dicot Pharma AB ("Dicot Pharma" or the "Company") has now received indications of interest from certain major shareholders totaling approximately SEK 15.6 million in the... ► Artikel lesen | |
| 20.05. | Dicot Pharma AB: Dicot Pharma completes tablet manufacturing ahead of phase 2b clinical study | 370 | GlobeNewswire (Europe) | Uppsala, Sweden, May 20, 2026. Dicot Pharma AB announces that the company has successfully completed manufacturing of the drug candidate LIB-01 as a tablet for the planned phase 2b study, which is intended... ► Artikel lesen | |
| 19.05. | Dicot Pharma AB: Dicot Pharma publishes prospectus in connection with the forthcoming rights issue | 375 | GlobeNewswire (Europe) | Dicot Pharma AB ("Dicot Pharma" or the "Company") today, on May 19, 2026, publishes an EU Follow-on Prospectus (the "Prospectus") in connection with the rights issue of units, consisting of shares and... ► Artikel lesen | |
| 08.05. | Dicot Pharma AB: Dicot Pharma has resolved on an 80% guaranteed rights issue of approximately SEK 210 million | 1.071 | GlobeNewswire (Europe) | Uppsala, Sweden, May 8, 2026. The Board of Directors of Dicot Pharma AB ("Dicot Pharma" or the "Company") announced on April 28, 2026 its intention to resolve on a rights issue with preferential rights... ► Artikel lesen | |
| 06.05. | Dicot Pharma AB: Report from the Annual General Meeting of Dicot Pharma | 322 | GlobeNewswire (Europe) | Uppsala, Sweden, May 6, 2026. Dicot Pharma AB held its Annual General Meeting today in Uppsala where the following decisions were made.
Annual report and resultsThe meeting adopted the income statements... ► Artikel lesen | |
| 30.04. | Dicot Pharma AB: Dicot Pharma presents interim report Q1 2026 and invites to a webcast | 376 | GlobeNewswire (Europe) | Uppsala, Sweden, April 30, 2026. Dicot Pharma AB publishes its interim report for the first quarter of 2026. The report is available as an attached document and on www.dicotpharma.com. The company will... ► Artikel lesen | |
| 28.04. | Dicot Pharma AB: Dicot Pharma intends to carry out an 80% already secured rights issue of SEK 210 million | 733 | GlobeNewswire (Europe) | Uppsala, Sweden, April 28, 2026. The Board of Directors of Dicot Pharma AB ("Dicot Pharma" or the "Company") intends to resolve on a rights issue of units, consisting of shares and warrants, corresponding... ► Artikel lesen | |
| 12.03. | Dicot Pharma AB: Dicot Pharma initiates tablet manufacturing ahead of phase 2b clinical study | 482 | GlobeNewswire (Europe) | Uppsala, Sweden, March 12, 2026. Dicot Pharma AB announces that the company has successfully completed the development of LIB-01 as a tablet and initiated manufacturing of tablets ahead of the upcoming... ► Artikel lesen | |
| 18.12.25 | Dicot Pharma AB: Dicot Pharma signs agreement with CRO ahead of phase 2b study with LIB-01 | 603 | GlobeNewswire (Europe) | Uppsala, Sweden, December 18, 2025. Dicot Pharma AB has signed an agreement with a global contract research organization (CRO) to prepare for the planned phase 2b clinical study of the drug candidate... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ETON PHARMACEUTICALS | 60,43 | 0,00 % | PAUL MAIER V At Eton Pharmaceuticals Executes Options Exercise, Realizing $2.84M | ||
| BAYER | 48,700 | -0,37 % | Nicht Micro-Chips, sondern Ernährung im Fokusl Was kommt auf den Tisch bei Mc Donalds, Bayer, MustGrow und Kraft Heinz? | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Die Börse ist vieles, aber wenig nachhaltig. Denn Trends wechseln wie das Wetter, Chips heute hui, morgen Chips pfui. Die Argumentationsketten... ► Artikel lesen | |
| MERCK KGAA | 138,70 | -0,75 % | Aktien Frankfurt Ausblick: Dax knapp im Minus - Rutsch unter 21-Tage-Linie | FRANKFURT (dpa-AFX) - Für den Dax zeichnen sich nach dem schwachen Wochenauftakt am Dienstag weitere moderate Verluste ab. Eine Stunde vor Handelsbeginn signalisierte der X-Dax als außerbörslicher... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 15,770 | -0,13 % | Generate Biomedicines stock price target raised to $30 by H.C. Wainwright on asthma data | ||
| KAZIA THERAPEUTICS | 12,640 | 0,00 % | Kazia Therapeutics Limited: Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy | Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 5,225 | 0,00 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Successfully completed human factors validation study and pharmacokinetic study for Anaphylm (dibutepinephrine) sublingual filmRemains on track to resubmit Anaphylm NDA to the FDA in Q3 2026Continues... ► Artikel lesen | |
| NOVO NORDISK | 39,550 | +1,40 % | Aktie rutscht ab: Novo Nordisk wird auf Sell abgestuft - und die Zweifel reichen bis 2027 | © Foto: Steffen Trumpf - dpaDas neue Kursziel der Deutschen Bank liegt klar unter dem aktuellen Börsenkurs. Gleichzeitig rückt die Wegovy-Pille in China einen Schritt näher an den Markt Enthaltene Werte:... ► Artikel lesen | |
| APNIMED | 26,870 | +0,07 % | Apnimed, Inc.: Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization... ► Artikel lesen | |
| KARDIGAN | 19,670 | 0,00 % | Citi's U.S. Consumer Cards Business To Buy Kard Financial For Undisclosed Terms | WASHINGTON (dpa-AFX) - Banking major Citigroup Inc. (C) announced late Thursday that its U.S. Consumer Cards business has agreed to acquire Kard Financial, a commerce media and rewards platform.... ► Artikel lesen | |
| LB PHARMACEUTICALS | 47,060 | 0,00 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027 Announced plans for pipeline expansion of LB-102 into... ► Artikel lesen | |
| PFIZER | 24,695 | +0,22 % | Gewinner der Börsengeschichte: Kaum ein Deutscher kennt diese Heißzeit-Aktie - Sie brachte +3.923.693% Rendite! | © Foto: Christoph Hardt/Geisler-Fotopress - Geisler-FotopressDer US-amerikanische Anbieter von Klimalösungen Trane Technologies gilt als Profiteur des Klimawandels. Die Buy-and-Hold-Gesamtrendite liegt... ► Artikel lesen | |
| MILESTONE PHARMACEUTICALS | 1,140 | 0,00 % | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients' Daily Lives and Quality of Life Between Episodes | ||
| OMNIAB | 4,435 | 0,00 % | Veraxa Biotech AG: VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb | VXA-222 advances into next phase at VERAXAZURICH, SWITZERLAND, July 27, 2026 --
VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA" or the "Company"), an emerging leader in designing novel cancer therapies... ► Artikel lesen | |
| SANOFI | 76,89 | +0,16 % | Sanofi nach FDA-Erfolg: Was Anleger jetzt wissen müssen | ||
| CELLYAN BIOTECHNOLOGY | 0,182 | 0,00 % | Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period | HONG KONG, July 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply... ► Artikel lesen |
DICOT PHARMA AB gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +5,84 % bei einem Aktienkurs von 0,015 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DICOT PHARMA AB finden Sie auf Wallstreet Online.